Atlas Trials

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

Clinical trial NCT07460362 · RECRUITING

Trial details

NCT number
NCT07460362
Sponsor
Peking University Third Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
MCLRelapsed or Refractory Mantle Cell Lymphoma (MCL)
Start date
2025-08-11
Primary completion
2027-12-30
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.